Gil MM

Idioma: Español
Referencias bibliográficas: 16
Paginas: 44-47
Archivo PDF: 53.01 Kb.

RESUMEN

Los procedimientos de intervención coronaria percutánea tienen, hoy en día, una clara preferencia en el tratamiento de los síndromes coronarios agudos. Dada la importancia que las plaquetas y la formación de fibrina tienen en la fisiopatología de estos cuadros clínicos y en la génesis de las posibles complicaciones de los procedimientos intervencionistas, la asociación de los mismos con medicamentos que controlan la respuesta trombogénica y coagulante, ha tenido por consecuencia una reducción significativa de los reinfartos, muertes y reintervenciones en el vaso tratado o cirugía de urgencia. Por sus efectos sinérgicos con las intervenciones coronarias percutáneas, la aspirina, el clopidogrel, las heparinas (fraccionadas y no fraccionadas) y los bloqueadores de los receptores plaquetarios IIb/IIIa ha pasado a formar parte muy importante de la terapia de los síndromes coronarios isquémicos agudos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Smith SC, Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al: ACC/HAH Guidelines for Percutaneous Coronary Interventions: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001; 37: 2239i-Ixvi.

2. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, et al: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-1840.

3. Brunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al: ACC/AHA guidelines uptade for the management of patients with unstable angina and non-ST-elevation myocardial infarction: summary article. J Am Coll Cardiol 2002:40;1366-1374.

4. Metha SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al: Effects of pretreatment with clopidogrel and aspirine followed be long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533.

5. Steinhubl S, Berger PB, Mann J, Fry ET, De Lago A, Wilmer C, Topol EJ: Early and susstained dual oral antiplatelet therapy following percutaneous coronary interventions: a randomized trial. JAMA 2002; 288: 2411-2420.

6. Vivekananthan DP, Bhatt DL, Chew DP, Chan AW, Moliterno DJ, Ellis SG, Topol EJ: Clopidogrel pretreatment prior to percutaneous coronary intervention attenuates periprocedural rise of C-Reactive Protein. J Am Coll Cardiol 2003; 41 (suppl A): A165.

7. Bertand ME, Rupprecht HJ, Urban P, Gershlick AH: Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.

8. Wong GC, Giugliano RP, Antman EM: Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 2003; 289: 331-342.

9. The CAPTURE Investigators: Randomized placebo-controlled trial of abciximab before an during coronary interventions in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-1435.

10. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-1453.

11. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald EI: Invasive versus conservative strategies in unstable angina and non-Q wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTlCS-TIMI 18 trial. Treat Angina With Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy. Thrombolysis in Myocardial Infarction 18. Am J Cardiol 1998; 82: 731-736.

12. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-961.

13. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.

14. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Investigators: Randomized placebo-controlled and balloon, angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/lIla blockade. Lancet 1998; 352: 87-92.

15. Integrilin to minimize platelet aggregation and coronary thrombosis-II (IMPACT-II) Investigators: Randomized placebo controlled trial of effect of eptifibatide on complications of percutaneous coronary interventions. Lancet 1997; 349: 1422-1428.

16. Topol EJ, Moliterno DJ, Herremann HC, Powers ER, Grines JL, Cohen DJ, et al: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, Tirofiban and Abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-94.